Intercept Pharma (ICPT) Misses Q4 EPS by 88c, Miss on Revenues

Note: EPS may not comparable

Intercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($4.43), $0.88 worse than the analyst estimate of ($3.55). Revenue for the quarter came in at $37.3 million versus the consensus estimate of $39.03 million.

• Worldwide Net Ocaliva® (obeticholic acid or OCA) full year 2017 net sales of $129.2 million, fourth quarter 2017 sales of $37.3 million
• U.S. Prescribing Information for Ocaliva® updated to reinforce appropriate dosing in PBC patients with advanced cirrhosis
• Continuing to advance industry leading NASH Phase 3 program: REGENERATE trial in NASH fibrosis on track to report data in 1H19; REVERSE trial in NASH cirrhosis enrolling

For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15